Lamivudine / zidovudine
Adults and children ages 12 and older weighing over 50 kg (110 lb): one tablet P.O. b.i.d.
CNS: headache, malaise,jatigue, insomnia, dizziness, neuropathy, depression.
EENT: nasal signs and symptoms.
GI: nausea, diarrhea, vomiting, anorexia, abdominal pain, abdominal cramps, dyspepsia.
Hematologic: neutropenia, anemia.
Hepatic: increased ALT, AST, amylase.
Musculoskeletal: musculoskeletal pain, myalgia, arthralgia.
Other: fever, chills.
Drug-drug. Ganciclovir, interferonalpha, other bone marrow suppressive or cytotoxic agents: may increase zidovudine's hematologic toxicity. Monitor patient.
EFFECTS ON DIAGNOSTIC TESTS
Contraindicated in patients with known hypersensitivity to drug's components and in those requiring dosage adjustments, such as children under age 12, those weighing under 50 kg, and those with creatinine clearance below 50 ml/minute. Also contraindicated in patients experiencing dose-limiting adverse effects.
Use combination cautiously in patients with bone marrow suppression as evidenced by granulocyte count below 1,000 cells/mm3 or hemoglobin level below 9.5 g/dl.
Lactic acidosis and severe hepatomegaly with steatosis have been reported in patients receiving lamivudine and zidovudine alone and in combination. The health care provider is notified if signs of lactic acidosis or hepatotoxicity develop (abdominal pain, jaundice).
Bone marrow toxicity must be monitored by frequent blood counts, particularly in patients with advanced HIV infection. Patients should be monitored for signs and symptoms oflactic acidosis and hepatotoxicity.
A patient's fine motor skills and peripheral sensation should be assessed for evidence of peripheral neuropathies.
An Antiretroviral Pregnancy Registry has been established to monitor maternalfetal outcomes of pregnant women exposed to Combivir. To register a pregnant patient, health care provider can call 1-800-258-4263.
The lamivudinelzidovudine combination drug therapy is not a cure for HTV infection; illness, including opportunistic infections, may continue to occur.
HIV transmission can still occur with drug therapy.
Use protection when engaging in sexual activities to prevent disease transmission.
Signs and symptoms of neutropenia and anemia include fever, chills, infection, fatigue; report such occurrences.
Blood counts should be followed closely while on drug, especially ifthere is advanced disease.
Consult health care provider or a pharmacist before taking other drugs.
Report abdominal pain immediately.
Report signs and symptoms of myopathy or myositis (muscle inflammation, pain, weakness, decrease in muscle size).
Take combination drug therapy exactly as prescribed to reduce the development of resistance.
Combination may be taken with or without food.
Breast-feeding is contraindicated in my infection and during drug therapy
Source: Free Articles from ArticlesFactory.com
ABOUT THE AUTHOR
Useful information on various drugs with their uses and benefits. If you like the above article, you are free to publish it on your ezine or website, you just need to publish this resource box along with the article, with a live link to : http://www.drugsblog.org.